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Objectives: To determine differences between PTA and conventional medical treatment in treadmill distance until onset 
of claudication, treadmill maximum walking distance, patient reported maximum walking distance, ankle brachial pressure 
index (ABPI), quality of life (Nottingham Health Profile, NHP) and Duplex measured extent of occlusive disease. 
Design: Randomised controlled clinical trial. 
Methods: Six hundred claudicants were screened. Fifty-one men and 11 women with intermittent claudication due to short 
femoral stenoses or occlusions (n = 47) and iliac stenoses (n = 15) were randomised to either PTA plus medical treatment 
(PTA group, n = 30) or to medical treatment alone (control group, n = 32). Medical treatment consisted of daily low dose 
aspirin and advice on smoking and exercise. 
Results: At 6 month follow up: In the PTA group more patients reported no claudication (p <_ 0.05) and were asymptomatic 
on the treadmill (p ~- 0.0I) compared to the control group. The ABPI was significantly higher in the PTA group. More of 
the PTA group reported lower NHP pain scores (p~O.05). In the control group there were more occluded arteries 
(p ~- 0.001), and the stenosis velocity ratio of patent arteries was significantly higher (p ~_ 0.001). 
Conclusions: Only 10% of claudicants had discrete lesions suitable for PTA. Treatment of these patients with PTA 
produces agreater short-term improvement in walking and quality of life than medical treatment alone and is associated 
with less progression of disease. 
Key Words: Angioplasty; Intermittent claudication; Femoral artery; Iliac artery; Randomised controlled trial. 
Introduction 
Percutaneous transluminal angioplasty (PTA) is an 
accepted method of treatment of critical limb ischae- 
mia. 1~ Although PTA is also widely used in the 
management of intermittent claudication its true value 
in this situation is more controversial. 5-7 It has gained 
acceptance despite the known spontaneous improve- 
ment in claudication which occurs particularly with 
cessation of smoking and continued walking. 8 The 
dilemma over the opt imum treatment of claudication 
is exemplified in the following contrasting statements: 
"These results justify the use of angioplasty in the 
treatment of intermittent claudication. " l "Conserva- 
tive therapy should be primary treatment. Invasive 
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procedures (angioplastN etc) should be reserved for 
the treatment of limb threatening events. "5 "It is 
debatable whether such a randomised controlled trial 
of PTA would now be considered ethical. "6 
The natural history of intermittent claudication has 
been documented in a number of large studies. 9-~5 
Significant deterioration in symptoms occurs in 
25-35% of patients over 3-5 years and amputation is
required in 1-2% per year.9' l°Improvement in symp- 
toms with persistent exercise is common but can take 
as long as a year. 16'17 In contrast, the improvement in
symptoms resulting from a technically successful 
angioplasty is usually immediate. Five year patency 
rates of 60-90% for iliac disease and 40-70% for 
femoral disease have been reported. 2~4 Major compli- 
cations occur in 1% of claudicants) However, the only 
controlled trial comparing angioplasty with non- 
surgical treatment (intensive walking therapy) failed 
to show any important benefits from angioplasty. 16'18 
The aim of this study was to compare angioplasty 
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versus conservative treatment of intermittent claudi- 
cation in a controlled clinical trial in terms of reported 
maximum walking distance, treadmill onset of claudi- 
cation distance, treadmill maximum walking distance, 
ankle brachial pressure index (ABPI), arterial patency 
and quality of life 6 months after randomisation. 
Follow-up is evaluating late outcome. 
Methods 
Between 1991 and 1993 all patients referred to the 
peripheral vascular clinic at the Royal Infirmary of 
Edinburgh with predominantly unilateral intermittent 
claudication were considered for inclusion in the trial. 
Exclusion criteria were: previous angioplasty or arte- 
rial surgery to the symptomatic leg, myocardial 
infarction within the previous 6 months, patients 
taking oral anticoagulants, duration of symptoms less 
than 1 month, inability to manage the treadmill 
examination, and any psychiatric illness or other 
reason making follow-up difficult. 
In the clinic a routine history and physical examina- 
tion were performed. Patients were asked to estimate 
their maximum walking distance on the flat under 
normal conditions (reported maximum walking dis- 
tance). A venous blood sample was taken for plasma 
total cholesterol estimation. After the patient had 
rested supine for 10 min right brachial and right and 
left ankle systolic pressures were measured using 
Doppler probe and random zero sphygmomanometer 
(Hawksley & Son Ltd, Lancing, Surrey, U.K.). Weight 
and height were measured (instrument by Seca-Delta, 
Germany) in light clothing without shoes. Patients 
completed the Nottingham Health Profile ~9 which 
enquires about six modalities of quality of life: pain, 
mobilit3~ sleep, emotion, energy and isolation. A 
standard treadmill test (4 km/h at 10% incline) was 
performed measuring the time to onset of claudication 
and the time to cessation of walking due to claudica- 
tion, up to a maximum of 10 min. These were 
converted to distances: treadmill onset claudication 
distance, and treadmill maximum walking distance. 
The symptomatic leg was examined after rest by 
colour Duplex using an ATL UM9 (HDI) machine 
(Advanced Technology Laboratories, Bothell, WA, 
U.S.A.). Lesions considered suitable for PTA were 
discrete femoral or iliac stenoses or femoropopliteal 
occlusions _< 10 cm long. Patients were excluded from 
further study if they were found to have iliac 
occlusion, > 10 cm length femoropopliteal occlusion, 
multiple stenoses or diffuse disease with long steno- 
ses. Patients who had lesions suitable for PTA identi- 
fled on Duplex scanning then underwent percuta- 
neous transfemoral rteriography. Those with lesions 
confrmed as suitable for PTA were randomised to 
either conventional medical treatment (low dose 
aspirin plus advice on smoking and exercise) or PTA 
by balloon dilatation plus the same medical treatment. 
With regard to exercise, patients were advised to 
continue to walk as far as possible and as frequently as 
possible within the limits imposed by pain. The 
randomisation was made by means of a telephone link 
to a computerised random allocation system provided 
by the Scottish Cancer Trials Office, University of 
Edinburgh. In most cases PTA was carried out in the 
same session as the arteriography. 
Patients were followed up 3 and 6 months after 
randomisation. At follow up, several of the procedures 
carried out at baseline were repeated: treadmill 
exercise test, measurement of ABPI and completion of 
the Nottingham Health Profile questionnaire. Duplex 
ultrasound was also carried out to determine if the 
arterial site in question was patent or occluded, and if 
patent o assess the degree of stenosis expressed as the 
velocity ratio. 2°'21 
Analysis was carried out using the statistical pack- 
age SPSS-X. The walking distances were converted to 
binary variables: reported ability to walk 1 km; no 
symptoms after 667 m on the treadmill and the ability 
to reach 667 m on the treadmill. Chi-squared and 
Fisher's exact test were used to examine categorical 
differences whilst students t-test and Mann-Whitney 
U-test were used to examine ordinal differences 
between the PTA and control group at randomisation 
and after 6 months. Two-tailed p-values are given. The 
sample size was calculated as follows: A significant 
difference between two groups of 27 patients hould 
be detected if significant symptomatic improvement 
occurred in 20% of the control group and 60% of the 
PTA group with a power of 90% and a type I error of 
0.05. Significant improvement was arbitrarily taken as 
the ability to walk 667 m (10 min) on the treadmill free 
of pain where this was not possible before. Approval 
for the trial was obtained in advance from the 
Research Ethics Sub-Committee for Surgery. Written 
consent was obtained from all patients undergoing 
angiography. 
Results 
Approximately 600 claudicants were seen in the out- 
patients department between 1991 and 1993. Of these, 
425 were initially considered suitable for trial entry 
and were subjected to duplex scanning. 316 patients 
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did not fulfil the inclusion criteria on the basis of 
Duplex findings and an additional 15 did not wish to 
participate in the trial at this stage. The remainder (94 
patients) underwent ransfemoral arteriography fol- 
lowing which another 32 were excluded from the trial. 
Thus, 62 patients had disease suitable for PTA and 
were randomised. 
patients was as follows: death from myocardial 
infarction (1), non-attendance (2), patients inability to 
walk well due to recent colonic cancer surgery (1) and 
vein harvesting for coronary artery bypass graft (1), 
severe angina (1), new myocardial infarction (1), 
temporari ly faulty treadmill machine (1) and non- 
specific illness (1). 
Randomisation 
Randomisation allocated 30 patients to the PTA and 32 
to the control group. The length of femoral occlusions 
in both groups was comparable: median 3cm (range 
1-10) in the PTA group and median 4cm (range 2-8) in 
the control group. Table 1 shows the age, sex, 
occurrence of cardiovascular risk factors, severity of 
arterial disease and site and types of lesion in the two 
groups. No statistically significant differences were 
found between the two groups (p > 0.05). 
Follow-up 
At 6 months follow up no patient in either group had 
required surgery for critical ischaemia or deterioration 
of symptoms. No patients had opted out of the trial. 
Three patients in the angioplasty group also had 
angioplasty of the other leg within 6 months of 
randomisation. The reasons for incomplete data on the 
exercise treadmill or on Duplex scanning in some 
Differences in walking and ABPI between PTA and 
control groups at 6 months 
Table 2 shows the severity of arterial disease in the 
PTA and control groups at 6 months. The PTA group 
had significantly more patients with a reported walk- 
ing distance of lkm (p ___ 0.05) and without claudication 
on treadmill exercise (p__. 0.01). The PTA group also 
had a significantly greater ABPI (p <_ 0.01). 
Further analysis was carried out separately on 
femoral and iliac lesions. In the 15 patients with iliac 
lesions there were no demonstrable differences 
between PTA and control groups in the numbers 
reporting a walking distance of lkm, the number free 
of claudication on the treadmill, the number who 
could walk the maximum distance on the treadmil l  or 
in ABPI. However, in the 47 patients with femoral 
lesions the PTA group had significantly more patients 
who reported a walking distance of 1kin (p ___ 0.05) and 
who did not have claudication on treadmill exercise 
(p_< 0.01) in addition to having a significantly greater 
ABPI (p _< 0.01). The small number of patients with iliac 
Table 1. Baseline characteristics o f  PTA and control groups 
PTA (n=30) Control (n=32) 
Age and Sex 
Age-mean (range) years 
Males-n 
Cardiovascular Risk Factors 
Current smokers-n 
Serum cholesterol-mean (s.E.) mmol/1 
Systolic blood pressure-mean (s.E.) mmHg 
Body mass index-mean (s.E.) kg/m 2 
Diabetes mellitus-n 
Severity of disease 
Reported maximum walking distance inmetres-median (IQR) 
Treadmill distance in metres until onset claudication-median (IQR) 
Treadmill maximum walking distance in metres-median (IQR) 
Ankle brachial pressure index-mean (s.E.) 
Site and Type of Lesion 
Number of femoral occlusions 
Number of femoral stenoses 
Number of iliac stenoses 
Duplex Velocity Ratio of stenoses-median (IQR) 
60.6 (44-73) 62.6 (45-78) 
23 28 
15 16 
6.69 (0.26) 6.44 (0.33) 
157.9 (4.1) 155.4 (3.5) 
25.78 (0.50) 26.20 (0.70) 
4 1 
200 (100-425) 200 (100-430) 
56 (33-133) 78 (56-100) 
228 (77-442) 183 (117-519) 




4.55 (3.67-5.00) (n=19) 5.33 (3.45-7.50) (n=21) 
All differences between PTA and control groups were non-significant (p>0.05). 
IQR, interquartile range. 
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Table 2. Severity of peripheral arterial disease in PTA and control groups at 6 months 
PTA Control 
group group p-value 
Number with lkm reported walking distance 
Reported walking distance-median (IQR) 
Number without claudication on treadmill exercise 
Treadmill distance until onset claudication-median (IQR) 
Number walking maximum distance on treadmill exercise 
Treadmill maximum walking distance-median (IQR) 
Ankle brachial pressure index-mean (s.E.) 
Number with occlusion 
Duplex Velocity Ratio-median (IQR) 
19 / 28 11/28 -<0.05 
999 (325-999) 450 (200-999) NS 
18/26 6/27 -<0.01 
667 (158.5-667) 172 (69.3-650.3) -<0.05 
18/26 13/27 NS 
667(219.3-667) 519.5 (132.8~67) NS 
0.88 (0.03) 0.74 (0.03) -<0.01 
(n=29) (n=30) 
1/28 12/29 -<0.001 
2.20 (1.67-3.10) 4.50 (3.95-7.87) -<0.001 
IQR, interquartile range. 
lesions makes interpretation f the clinical significance 
of these findings difficult. 
Differences in lesion progression at 6 months 
In the control group three new occlusions developed 
during follow-up. In the PTA group all seven occlu- 
sions were initially rendered patent, but one reoc- 
cluded during follow-up. Thus, there were a sig- 
nificantly greater number of occluded arteries in the 
control group than the PTA group at 6 months 
(p ___ 0.001). In arteries remaining patent, the degree of 
narrowing at the stenosis (velocity ratio) was sig- 
nificantly less in the PTA group (p < 0.001). In neither 
group was a lesion measured as longer than 10cm at 6 
months so that, in principle, all were amenable to 
angioplasty. 
Differences in quality of life at 6 months 
The number of subjects responding 'yes' to one or 
more questions in each of the six aspects of life in the 
NHP is shown in Table 3. At randomisation there were 
no significant differences in any of the modalities 
between the two groups (p > 0.05). However, at the 6 
month follow up the PTA group had a lower pain 
score (p _< 0.05), but there were no differences between 
the two groups in the other quality of life modalities 
(p > 0.05). 
Discussion 
An interesting finding in this study was that 90% of 
the patients with intermittent claudication who were 
screened were, in fact, unsuitable for treatment by 
PTA either because of the pattern of their occlusive 
disease or because of other diseases. When a suitable 
lesion is present, however, the results of this trial have 
demonstrated that, in the short term, claudicants 
treated by PTA have less pain, improved walking and 
greater resting ABPI than patients managed con- 
servatively. In particular, after PTA more patients are 
able to walk a set distance before the onset of pain. 
The only other reported randomised trial of PTA 
versus non-surgical treatment found intensive walk- 
ing therapy to be similar to PTA in terms of maximum 
walking distance and daudication distance on the 
treadmill at a mean follow up of 69 months. 18 
Furthermore, there did not appear to be a significant 
difference in ABPI between the two groups and the 
mean ABPI was lower in both groups than in this trial. 
A possible xplanation is that patients might have had 
more severe disease than in this trial and indeed, our 
trial was exclusively concerned with patients with 
discrete, single segment atheromatous lesions. One 
reason for reporting the 6 months results of this trial 
Table 3. Nottingham Health Profile scores in PTA and control group 
at baseline and at 6 months 
Baseline 6 Months 
PTA Control PTA Control 
(n=30) (n=32) p=value (n=30) (n=32) p=value 
Energy 8 13 NS 5 8 NS 
(n=28) (n=28) 
Pain 26 29 NS 12 21 -<0.05 
(n=28) (n=27) 
Emotion 10 18 NS 7 3 NS 
(n=28) (n=27) 
Sleep 17 11 NS 11 7 NS 
(n=28) (n=28) 
Isolation 5 4 NS 1 1 NS 
(n=28) (n=28) 
Mobility 16 19 NS 6 10 NS 
(n=28) (n=28) 
Values are the number of subjects responding 'yes' to one or more 
questions in each of the six of quality life indices. 
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now is that, based on the results of the earlier trial, 
some vascular specialists might be tempted to aban- 
don PTA in favour of intensive walking therapy. The 
results from our trial cannot refute this since patients 
were not offered intensive walking therapy. However, 
we would suggest hat it is justified to offer patients 
PTA in the expectation that their walking should be 
better in the short term than if they receive the most 
widely accepted form of non-interventional treatment, 
that is advice on smoking and walking and often low 
dose aspirin. 
The improvement in walking after PTA should be 
reflected in an improved quality of life. The results 
presented here show that after 6 months more of the 
PTA group reported lower pain scores. The Notting- 
ham Health Profile has been well validated and used 
in patients with more severe peripheral vascular 
disease, 19 after coronary artery bypass, 22 stroke z3 and 
with osteoarthritis. 24 However, one of the disadvan- 
tages of the scoring, particularly with "milder" disease 
such as intermittent claudication, is that a very high 
proportion of the answers is returned as "no", so that 
patients' quality of life has to be markedly impaired 
before a difference between treatment groups can be 
established. This makes the differences found in this 
study all the more important, but a more sensitive 
questionnaire might well have detected other differ- 
ences. Many would argue that the use of the Notting- 
ham Health Profile has now been superseded by 
quality of life scores uch as the Short Form Outcomes 
Questionnaire (SF-36). 25 Interestingl)4 the latter has 
recently been used to compare (in a non-randomised 
study) the differences between claudicants under- 
going angioplasty and those being treated conserva- 
tively, with the former showing greater improvement 
in some quality of life modalities. 26 
There are few objective endpoints which can be 
used to demonstrate the superiority of any form of 
treatment of claudication. Treadmill exercise testing 
can be considered a somewhat subjective index of 
disease severity, but it is widely used in clinical 
research and in this study it has provided supportive 
evidence of the patient's assessment of his or her 
walking ability. Some have found walking distance to 
be poorly reproducible, 27whilst others have shown a 
good correlation between claudication distance and 
ankle pressure. 2s It therefore seems reasonable to use 
the test within the confines of a randomised study. 
Patient reported maximum walking distance is subject 
to considerable bias including a placebo effect in a trial 
such as this. However, it could be argued that it does 
not matter to what extent patients benefit from a 
placebo effect providing they feel better, and this trial 
has demonstrated that they do feel better 6 months 
after angioplasty. 
The differences between PTA and control groups at 
6 months were not only statistically but also clinically 
significant. Despite a substantial improvement in 
walking in both groups over 6 months the median 
reported walking distance in the PTA group (lkm) 
was more than double that in the control group 
(< 1/2km) and the median treadmill distance until 
onset of claudication was four times greater in the PTA 
group (667m) than in the control group (172m). This 
magnitude of difference can be very important in 
terms of pain free achievement of the activities of daily 
living. 
The trial has also shown that, in the short term, the 
deterioration of occlusive arterial disease in the legs is 
reduced after PTA. There were more occlusions in the 
control group and the stenoses were more severe. This 
is potentially an important finding but it is too early to 
know if this ultimately influences limb survival. 
Furthermore, occluded vessels may have a protective 
effect on the development of atheroma in the distal 
circulation 29 and PTA, in contrast o reducing disease 
progression, could enhance it. In considering the 
optimum treatment for claudication, a reduction in the 
need for amputation and reconstructive surgery is of 
paramount importance. However, such a trial would 
require several thousand patients and was beyond the 
scope of this study. Clearly, more detailed studies are 
required to explore this area. 
In addition to the relative benefits in terms of 
symptomatic relief, there are other factors which need 
to be considered. These include the immediate risk of 
PTA, its consumption of resources, patient discomfort 
and inconvenience, the late impact on progression of 
disease with any method of intervention, and perhaps 
the ability to modify other cardiovascular risk factors 
such as body weight by improved exercise. Clearly, 
these hypotheses have not been tested in this trial. 
Nevertheless, there is a strong suggestion that exercise 
can favourably alter risk factors for atherosclerosis 
such as blood rheolog34 lipid profile, body weight, and 
hypertension and diabetic control. 3°'31 It would not, 
therefore, be unreasonable to postulate that improved 
walking after PTA has the potential to modify cardio- 
vascular risk factors. There is also the question of 
whether, by not treating a simple lesion by angio- 
plasty, a "window of opportunity" is missed after 
which treatment becomes more difficult and less 
successful. However, it is interesting that after a 
period of 6 months none of the patients in either group 
had lesions which had progressed to a point where 
they could not be treated by angioplasty. 
Intermittent claudication accounts for a very large 
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proportion of a vascular surgeon's out-patient work- 
load, and PTA is a treatment option which has been 
available for about 20 years. 32 Despite this, very few 
controlled clinical trials have compared it with other 
treatments. 16'33 To our knowledge, this is the first 
report of a controlled trial showing an improvement in 
walking and quality of life after PTA. We conclude 
that in patients with claudication due to single discrete 
femoral artery lesions PTA offers a better outcome in 
the short term than best medical treatment alone. 
However, this is a preliminary report and further long 
term follow up is required to determine the extent o 
which these benefits are maintained. Also, larger 
studies are required to determine any effects on limb 
salvage and need for surgery. 
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